CSNpharm

CSNpharm logo

Csnpharm is committed to providing you with high quality products and outstanding services. We supply over 5000 bioactive compounds in stock, including inhibitors, agonists and natural products for laboratory and scientific use. Csnpharm has always been committed to develop quality products that are validated by NMR, UPLC, LC-MS, GC, Chiral HPLC and so on. We have a professional technical support team for customer service with years of experience in life science. Csnpharm is your reliable partner for scientific research.

Company Website

Product Listing

Castanospermine 50mg  | ≥98%

CSNpharm

Castanospermine inhibits all forms of α- and β-glucosidases, especially glucosidase l (required for glucoprotein processing by transfer of mannose and glucose from asparagine-linked lipids).

More Information Supplier Page

Catalpol 10mg  | ≥99%

CSNpharm

Catalpol is a naturally occuring iridoid glucoside which exhibits anti-inflammatory activity and stimulates the production of adrenal cortical hormones.

More Information Supplier Page

Catalpol 50mg  | ≥99%

CSNpharm

Catalpol is a naturally occuring iridoid glucoside which exhibits anti-inflammatory activity and stimulates the production of adrenal cortical hormones.

More Information Supplier Page

Catechin 7-Xyloside 5mg  | ≥98%

CSNpharm

Catechin-7-O-xyloside, a natural product isolated and purified from ultrafine U. davidiana var. japonica ethanol extract, induces apoptosis via endoplasmic reticulum stress and mitochondrial dysfunction in human non-small cell lung carcinoma H1299 cells, suggests that it has anti-cancer activity.

More Information Supplier Page

Catharanthine 50mg  | ≥98%

CSNpharm

Catharanthine showed muscarinic antagonism at 10 μM and fully inhibited nicotinic receptor mediated diaphragm contractions with an IC50 of 59.6 μM. As a precursor of the anti-tumor drugs vinblastine and vincristine, it also works as an inhibitor of tubulin self-assembly into microtubules.

More Information Supplier Page

Catharanthine 100mg  | ≥98%

CSNpharm

Catharanthine showed muscarinic antagonism at 10 μM and fully inhibited nicotinic receptor mediated diaphragm contractions with an IC50 of 59.6 μM. As a precursor of the anti-tumor drugs vinblastine and vincristine, it also works as an inhibitor of tubulin self-assembly into microtubules.

More Information Supplier Page

Caulilexin C 5mg  | ≥98%

CSNpharm

Caulilexin C is a natural product isolated and purified from the herbs of Isatis idigotica, showing inhibitory activity on human Acyl CoA: cholesterol transferase I (hACATI) and on human Acyl CoA: cholesterol transferase 2 (hACAT2) at 100 ug/mL.

More Information Supplier Page

Caulilexin C 1mg  | ≥98%

CSNpharm

Caulilexin C is a natural product isolated and purified from the herbs of Isatis idigotica, showing inhibitory activity on human Acyl CoA: cholesterol transferase I (hACATI) and on human Acyl CoA: cholesterol transferase 2 (hACAT2) at 100 ug/mL.

More Information Supplier Page

CB 1954 50mg  | ≥98%

CSNpharm

CB 1954 is an anticancer prodrug used in gene therapy research and is activated by NAD(P)H Quinone Oxidoreductase 2.

More Information Supplier Page

CB 1954 25mg  | ≥98%

CSNpharm

CB 1954 is an anticancer prodrug used in gene therapy research and is activated by NAD(P)H Quinone Oxidoreductase 2.

More Information Supplier Page

CB 1954 10mg  | ≥98%

CSNpharm

CB 1954 is an anticancer prodrug used in gene therapy research and is activated by NAD(P)H Quinone Oxidoreductase 2.

More Information Supplier Page

CCI-006 5mg  | ≥99%

CSNpharm

CCI-006 is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias, inhibiting mitochondrial respiration and inducing mitochondrial membrane depolarization and apoptosis in a subset (7/11, 64%) of MLL-rearranged leukemia cell lines within a few hours of treatment.

More Information Supplier Page

CCI-006 100mg  | ≥99%

CSNpharm

CCI-006 is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias, inhibiting mitochondrial respiration and inducing mitochondrial membrane depolarization and apoptosis in a subset (7/11, 64%) of MLL-rearranged leukemia cell lines within a few hours of treatment.

More Information Supplier Page

CCI-006 25mg  | ≥99%

CSNpharm

CCI-006 is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias, inhibiting mitochondrial respiration and inducing mitochondrial membrane depolarization and apoptosis in a subset (7/11, 64%) of MLL-rearranged leukemia cell lines within a few hours of treatment.

More Information Supplier Page

CCI-006 10mg  | ≥99%

CSNpharm

CCI-006 is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias, inhibiting mitochondrial respiration and inducing mitochondrial membrane depolarization and apoptosis in a subset (7/11, 64%) of MLL-rearranged leukemia cell lines within a few hours of treatment.

More Information Supplier Page

CCI-006 1mg  | ≥99%

CSNpharm

CCI-006 is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias, inhibiting mitochondrial respiration and inducing mitochondrial membrane depolarization and apoptosis in a subset (7/11, 64%) of MLL-rearranged leukemia cell lines within a few hours of treatment.

More Information Supplier Page

CCI-006 50mg  | ≥99%

CSNpharm

CCI-006 is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias, inhibiting mitochondrial respiration and inducing mitochondrial membrane depolarization and apoptosis in a subset (7/11, 64%) of MLL-rearranged leukemia cell lines within a few hours of treatment.

More Information Supplier Page

CCT128930 HCl 10mg  | ≥98%

CSNpharm

CCT128930 is a potent ATP-competitive, selective Akt2 inhibitor with an IC50 of 6 nM and > 28-fold selectivity for Akt2 than the closely related PKA kinase.

More Information Supplier Page

CCT128930 HCl 25mg  | ≥98%

CSNpharm

CCT128930 is a potent ATP-competitive, selective Akt2 inhibitor with an IC50 of 6 nM and > 28-fold selectivity for Akt2 than the closely related PKA kinase.

More Information Supplier Page

CCT128930 HCl 100mg  | ≥98%

CSNpharm

CCT128930 is a potent ATP-competitive, selective Akt2 inhibitor with an IC50 of 6 nM and > 28-fold selectivity for Akt2 than the closely related PKA kinase.

More Information Supplier Page

CCT128930 HCl 50mg  | ≥98%

CSNpharm

CCT128930 is a potent ATP-competitive, selective Akt2 inhibitor with an IC50 of 6 nM and > 28-fold selectivity for Akt2 than the closely related PKA kinase.

More Information Supplier Page

CCT128930 HCl 5mg  | ≥98%

CSNpharm

CCT128930 is a potent ATP-competitive, selective Akt2 inhibitor with an IC50 of 6 nM and > 28-fold selectivity for Akt2 than the closely related PKA kinase.

More Information Supplier Page

CCT128930 HCl 1mg  | ≥98%

CSNpharm

CCT128930 is a potent ATP-competitive, selective Akt2 inhibitor with an IC50 of 6 nM and > 28-fold selectivity for Akt2 than the closely related PKA kinase.

More Information Supplier Page

CDDO-Im 1mg  | ≥98%

CSNpharm

CDDO-Im is a synthetic triterpenoid more potent than its parent compound CDDO both in vitro and in vivo and a PPARγ agonist.

More Information Supplier Page

CDDO-Im 10mg  | ≥98%

CSNpharm

CDDO-Im is a synthetic triterpenoid more potent than its parent compound CDDO both in vitro and in vivo and a PPARγ agonist.

More Information Supplier Page

CDDO-Im 5mg  | ≥98%

CSNpharm

CDDO-Im is a synthetic triterpenoid more potent than its parent compound CDDO both in vitro and in vivo and a PPARγ agonist.

More Information Supplier Page